Latest Articles

Epigenome editing has emerged as a tool that would likely pose fewer ethical issues compared to the permanence of genome editing. However, emerging research is demonstrating that epigenetic changes might be heritable, at least in some organisms.

Kerry Taylor-Smith explores the latest advances in synthetic biology, from the development of new agricultural biotechnology tools to therapeutics and diagnostics.

This article explores the latest technologies currently in use for transcriptomic research. It also highlights the latest advancements in transcriptomics technology, focusing on single-cell, spatiotemporal and the “dark-transcriptome”.

This article will explore the differences between genetically-modified and gene-edited organisms in food and agriculture, including the methods by which they are produced.

Technology Networks invited chief editor at Nature Biotechnology, Barbara Cheifet, to an Ask Me Anything session to answer questions about the biggest challenges in scientific publishing and how to get work published in high-ranking journals.

Using data provided by Intercontinental Exchange, My Green Lab has produced a report providing key insights into the current state of the sector’s carbon emissions. James Connelly highlights some of the key findings and their significance.

Neurodegenerative diseases are characterized by synapse dysfunction and the aggregation of proteins in the brain, which ultimately lead to neuronal loss. This article will review the studies and methods powering our growing understanding of the mechanisms behind neurodegenerative disease.

This article explores how biopharmaceutical organizations seeking to remain competitive must adopt innovations, like cell-free long DNA synthesis, to unleash the potential of synthetic biology and accelerate therapeutic development across all facets of genetic medicine.

Dr. Darrell Green's best friend, Ben, developed bone cancer and passed away just before his 14th birthday. This profile article explores how this experience stayed with Green, and has propelled his work towards a new treatment for bone cancer.

A diverse array of biological medicines are now used to prevent and treat a wide range of illnesses. This article will discuss the development of cell lines in biopharma and will touch on key considerations, such as future manufacturability.